Recombinant human serum albumin fusion proteins and novel applications in drug delivery and therapy

Current Pharmaceutical Design

Volumn 21, Issue 14, 2015, Pages 1899-1907

  Rogers, Brian ^a   Dong, Daoyuan ^b   Li, Zhijun ^b   Li, Zhiyu ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Albumin; Co delivery; Fatty acid modified drugs; Fusion protein; Intracellular targeting

Indexed keywords

ALPHA INTERFERON; BLOOD CLOTTING FACTOR 9; DRUG CARRIER; GLUCAGON LIKE PEPTIDE 1; GRANULOCYTE COLONY STIMULATING FACTOR; HYBRID PROTEIN; RECOMBINANT HUMAN SERUM ALBUMIN; SERUM ALBUMIN;

ARTICLE; CANCER CELL; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; FOOD AND DRUG ADMINISTRATION; HUMAN; NANOENCAPSULATION; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; TUMOR CELL; ANIMAL; CHEMISTRY; PROCEDURES; TRENDS;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN;

EID: 84930986759     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150302120047     Document Type: Article

References (75)

1. [1] Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta 2013; 1830: 5526-34.
2. [2] Shimanovich U, Bernardes GJ, Knowles TP, Cavaco-Paulo A. Protein micro-and nano-capsules for biomedical applications. Chem Soc Rev 2013; 43: 1361-71.
3. [3] Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008; 97: 4167-83.
4. [4] Elliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003; 21: 414-21.
5. [5] Schmidt SR. Fusion-proteins as biopharmaceuticals--applications and challenges. Curr Opin Drug Discov Devel 2009; 12: 284-95.
6. [6] Czajkowsky DM, Hu J, Shao Z, Pleass RJ. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med 2012; 4: 1015-28.
7. [7] Traynor K. Albiglutide approved for type 2 diabetes. Am J Health Syst Pharm 2014; 71: 888.
8. [8] Flisiak R, Flisiak I. Albinterferon-alpha 2b: a new treatment option for hepatitis C. Expert Opin Biol Ther 2010; 10: 1509-15.
9. [9] Joshi MR, Yao N, Myers KA, Li Z. Human serum albumin and p53-activating peptide fusion protein is able to promote apoptosis and deliver fatty acid-modified molecules. PLoS One 2013; 8: c.
10. [10] Sleep D. Albumin and its application in drug delivery. Expert Opin Drug Deliv, 2014; 12: 1-20.
11. [11] Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology 2005; 41: 1211-9.
12. [12] Soreide JA, Lea OA, Kvinnsland S. Cytosol albumin content in operable breast cancer. Correlations to steroid hormone receptors, other prognostic factors and prognosis. Acta Oncol 1991; 30: 797-802.
13. [13] Marfe G, Di Stefano C. Bypass mechanisms of resistance to tyrosine kinase inhibition in chronic myelogenous leukaemia. Curr Drug Discov Technol 2014; 11: 145-53.
14. [14] Terpe K. Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol 2003; 60: 523-33.
15. [15] Yuste R. Fluorescence microscopy today. Nat Methods 2005; 2: 902-4.
16. [16] Brandsma ME, Jevnikar AM, Ma S. Recombinant human transferrin: beyond iron binding and transport. Biotechnol Adv 2010; 29: 230-8.
17. [17] Fioravanti J, Medina-Echeverz J, Ardaiz N, et al. The fusion protein of IFN-alpha and apolipoprotein A-I crosses the blood-brain barrier by a saturable transport mechanism. J Immunol 2012; 188: 3988-92.
18. [18] Schellenberger V, Wang CW, Geething NC, et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol 2009; 27: 1186-90.
19. [19] de Bruyn M, Bremer E, Helfrich W. Antibody-based fusion proteins to target death receptors in cancer. Cancer Lett 2011; 332: 175-83.
20. [20] Duvic M, Talpur R. Optimizing denileukin diftitox (Ontak) therapy. Future Oncol 2008; 4: 457-69.
21. [21] Baker K, Qiao SW, Kuo TT, et al. Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells. Proc Natl Acad Sci USA 2011; 108: 9927-32.
22. [22] Desjarlais JR, Lazar GA. Modulation of antibody effector function. Exp Cell Res 2011; 317: 1278-85.
23. [23] Peters J, Theodore. All about Albumin: Biochemistry, Genetics, and Medical Applications. San Diego, Academic Press. 1996; 76-132
24. [24] Taguchi K, Chuang VT, Maruyama T, Otagiri M. Pharmaceutical aspects of the recombinant human serum albumin dimer: structural characteristics, biological properties, and medical applications. J Pharm Sci 2012; 101: 3033-46.
25. [25] Andersen JT, Dalhus B, Cameron J, et al. Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat Commun 2012; 3: 610.
26. [26] Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007; 113: 546-93.
27. [27] Chen X, Zaro JL, Shen WC. Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev 2012; 65: 1357-69.
28. [28] Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a longacting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 4810-7.
29. [29] Sugio S, Kashima A, Mochizuki S, et al. Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng 1999; 12: 439-46.
30. [30] Watanabe H, Yamasaki K, Kragh-Hansen U, et al. In vitro and in vivo properties of recombinant human serum albumin from Pichia pastoris purified by a method of short processing time. Pharm Res 2001; 18: 1775-81.
31. [31] Wang T, Gou Z, Wang F, et al. Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies. PLoS One 2014; 9: e103798.
32. [32] Barnett A. Exenatide. Expert Opin Pharmacother 2007; 8: 2593-608.
33. [33] Green BD, Gault VA, Mooney MH, et al. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues. Biol Chem 2004; 385: 169-77.
34. [34] Malone J, Trautmann M, Wilhelm K, et al. Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2009; 18: 359-67.
35. [35] Bush MA, Matthews JE, De Boever EH, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a longacting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab 2009; 11: 498-505.
36. [36] Huang YS, Chen Z, Chen YQ, et al. Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris. J Pept Sci 2008; 14: 588-95.
37. [37] Zhang L, Wang L, Meng Z, et al. A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys. Biochem Biophys Res Commun 2014; 445: 511-6.
38. [38] Jaitin DA, Roisman LC, Jaks E, et al. Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol Cell Biol 2006; 26: 1888-97.
39. [39] Grace MJ, Lee S, Bradshaw S, et al. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway. J Biol Chem 2005; 280: 6327-36.
40. [40] Foser S, Schacher A, Weyer KA, et al. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). Protein Expr Purif 2003; 30: 78-87.
41. [41] Wang YS, Youngster S, Grace M, et al. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 2002; 54: 547-70.
42. [42] Osborn BL, Olsen HS, Nardelli B, et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferonalpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002; 303: 540-8.
43. [43] Subramanian GM, Fiscella M, Lamouse-Smith A, et al. Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 2007; 25: 1411-9.
44. [44] Zeuzem S, Sulkowski MS, Lawitz EJ, et al. Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology 2010; 139: 1257-66.
45. [45] Zhao HL, Xue C, Wang Y, et al. Circumventing the heterogeneity and instability of human serum albumin-interferon-alpha2b fusion protein by altering its orientation. J Biotechnol 2007; 131: 245-52.
46. [46] Zhao HL, Yao XQ, Xue C, et al. Increasing the homogeneity, stability and activity of human serum albumin and interferon-alpha2b fusion protein by linker engineering. Protein Expr Purif 2008; 61: 73-7.
47. [47] Zhao HL, Xue C, Du JL, et al. Balancing the pharmacokinetics and pharmacodynamics of interferon-alpha2b and human serum albumin fusion protein by proteolytic or reductive cleavage increases its in vivo therapeutic efficacy. Mol Pharm 2012; 9: 664-70.
48. [48] Honjo E, Tamada T, Maeda Y, et al. Crystallization of a 2: 2 complex of granulocyte-colony stimulating factor (GCSF) with the ligand-binding region of the GCSF receptor. Acta Crystallogr Sect F Struct Biol Cryst Commun 2005; 61: 788-90.
49. [49] Morishita M, Leonard RC. Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor-expanding uses in cancer chemotherapy. Expert Opin Biol Ther 2008; 8: 993-1001.
50. [50] Volovat C, Gladkov OA, Bondarenko IM, et al. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy. Clin Breast Cancer 2014; 14: 101-8.
51. [51] Bjorkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 2001; 7: 133-9.
52. [52] Metzner HJ, Weimer T, Kronthaler U, et al. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 2009; 102: 634-44.
53. [53] Wunder A, Stehle G, Sinn H, et al. Enhanced albumin uptake by rat tumors. Int J Oncol 1997; 11: 497-507.
54. [54] Stehle G, Sinn H, Wunder A, et al. Plasma protein (albumin) catabolism by the tumor itself--implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol 1997; 26: 77-100.
55. [55] Lum H, Malik AB. Regulation of vascular endothelial barrier function. Am J Physiol 1994; 267: L223-41.
56. [56] Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-84.
57. [57] Desai NP, Trieu V, Hwang LY, et al. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbatebased docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008; 19: 899-909.
58. [58] Lindner JL, Loibl S, Denkert C, et al. Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapydagger. Ann Oncol 2014; 26: 95-100.
59. [59] Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008; 132: 171-83.
60. [60] Chen F, Wang W, El-Deiry WS. Current strategies to target p53 in cancer. Biochem Pharmacol 2010; 80: 724-30.
61. [61] Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 2005; 5: 3-8.
62. [62] Fischer PM, Lane DP. Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets? Trends Pharmacol Sci 2004; 25: 343-6.
63. [63] Kanovsky M, Raffo A, Drew L, et al. Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc Natl Acad Sci USA 2001; 98: 12438-43.
64. [64] Du AW, Stenzel MH. Drug carriers for the delivery of therapeutic peptides. Biomacromolecules 2014; 15: 1097-114.
65. [65] Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov Today 2012; 17: 850-60.
66. [66] Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23: 7794-803.
67. [67] Chawla SP, Chua VS, Hendifar AF, et al. A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma. Cancer 2015; 121: 570-9.
68. [68] Home P, Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother 2006; 7: 325-43.
69. [69] Curry S, Brick P, Franks NP. Fatty acid binding to human serum albumin: new insights from crystallographic studies. Biochim Biophys Acta 1999; 1441: 131-40.
70. [70] Singh Y, Palombo M, Sinko PJ. Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem 2008; 15: 1802-26.
71. [71] Zheng YR, Suntharalingam K, Johnstone TC, et al. Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery. J Am Chem Soc 2014; 136: 8790-8.
72. [72] Cordes AA, Carpenter JF, Randolph TW. Selective domain stabilization as a strategy to reduce human serum albumin-human granulocyte colony stimulating factor aggregation rate. J Pharm Sci 2012; 101: 2009-16.
73. [73] Osborn BL, Sekut L, Corcoran M, et al. Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur J Pharmacol 2002; 456: 149-58.
74. [74] Yao Z, Dai W, Perry J, et al. Effect of albumin fusion on the biodistribution of interleukin-2. Cancer Immunol Immunother 2004; 53: 404-10.
75. [75] Duttaroy A, Kanakaraj P, Osborn BL, et al. Development of a long-acting insulin analog using albumin fusion technology. Diabetes 2005; 54: 251-8.